The stock of EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has increased by 0.57 when compared to last closing price of 8.81. Despite this, the company has experienced a 7.39% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-12 that EyePoint Pharmaceuticals, Inc.’s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky ‘Buy’ call ahead of pivotal Phase 3 readouts in 2026. Duravyu’s potential for less frequent dosing could offer a key advantage over current market leaders Eylea and Vabysmo. Rapid enrollment in Phase 3 trials and robust safety/efficacy data boost confidence, but competition and market fragmentation remain significant risks.
Is It Worth Investing in EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Right Now?
The stock has a 36-month beta value of 1.65. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EYPT is 59.81M, and at present, short sellers hold a 11.98% of that float. On June 13, 2025, the average trading volume of EYPT was 829.82K shares.
EYPT’s Market Performance
The stock of EyePoint Pharmaceuticals Inc (EYPT) has seen a 7.39% increase in the past week, with a 49.92% rise in the past month, and a 29.72% gain in the past quarter. The volatility ratio for the week is 3.13%, and the volatility levels for the past 30 days are at 5.12% for EYPT. The simple moving average for the last 20 days is 21.79% for EYPT stock, with a simple moving average of 13.92% for the last 200 days.
Analysts’ Opinion of EYPT
Many brokerage firms have already submitted their reports for EYPT stocks, with Citigroup repeating the rating for EYPT by listing it as a “Buy.” The predicted price for EYPT in the upcoming period, according to Citigroup is $33 based on the research report published on January 07, 2025 of the current year 2025.
Jefferies gave a rating of “Buy” to EYPT, setting the target price at $15 in the report published on August 28th of the previous year.
EYPT Trading at 37.74% from the 50-Day Moving Average
After a stumble in the market that brought EYPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.65% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EYPT starting from Zaderej Karen L., who purchase 5,000 shares at the price of $5.99 back on May 19 ’25. After this action, Zaderej Karen L. now owns 36,500 shares of EyePoint Pharmaceuticals Inc, valued at $29,950 using the latest closing price.
Zaderej Karen L., the Director of EyePoint Pharmaceuticals Inc, purchase 5,000 shares at $5.81 during a trade that took place back on May 16 ’25, which means that Zaderej Karen L. is holding 31,500 shares at $29,050 based on the most recent closing price.
Stock Fundamentals for EYPT
Current profitability levels for the company are sitting at:
- -2.88 for the present operating margin
- 0.93 for the gross margin
The net margin for EyePoint Pharmaceuticals Inc stands at -2.62. The total capital return value is set at -0.5. Equity return is now at value -53.54, with -42.43 for asset returns.
Based on EyePoint Pharmaceuticals Inc (EYPT), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.15. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -11526.43.
Currently, EBITDA for the company is -129.23 million with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 9.79. The receivables turnover for the company is 126.79for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.85.
Conclusion
To sum up, EyePoint Pharmaceuticals Inc (EYPT) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
